Notably, the potency of ripretinib against KIT mutations observed in imatinib‐resistant patients was found to be superior to that of sunitinib in vitro, suggesting that ripretinib may be premium in post‐first‐line GIST. Here, KIT is linked to gastrointestinal stromal tumor.